These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 19207660)

  • 21. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 23. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 24. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 25. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
    Girolomoni G; Abeni D
    Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 29. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS
    N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
    [No Abstract]   [Full Text] [Related]  

  • 32. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
    Dereure O; Guillot B; Jorgensen C; Cohen JD; Combes B; Guilhou JJ
    Br J Dermatol; 2004 Aug; 151(2):506-7. PubMed ID: 15327565
    [No Abstract]   [Full Text] [Related]  

  • 33. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 34. Henoch-Schönlein purpura after etanercept therapy for psoriasis.
    Lee A; Kasama R; Evangelisto A; Elfenbein B; Falasca G
    J Clin Rheumatol; 2006 Oct; 12(5):249-51. PubMed ID: 17023811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
    Strober BE
    Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
    [No Abstract]   [Full Text] [Related]  

  • 36. Psoriatic onychopachydermoperiostitis: improvement with etanercept.
    Dans M; Hivnor C; van Voorhees AS
    Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482
    [No Abstract]   [Full Text] [Related]  

  • 37. Psoriasiform and pustular eruption induced by etanercept and infliximab.
    Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
    Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
    [No Abstract]   [Full Text] [Related]  

  • 38. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
    Richette P; Viguier M; Bachelez H; Bardin T
    J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
    [No Abstract]   [Full Text] [Related]  

  • 40. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
    Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
    Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.